Skip to main content
SpringerLink
Log in

Persönlichkeitsstörungen

  • Chapter
  • First Online:
Neuro-/Psychopharmaka im Kindes- und Jugendalter

  • 6036 Accesses

Zusammenfassung

Es gibt keine Studien zur Pharmakotherapie von Jugendlichen mit Persönlichkeitsstörungen. Deshalb muss die Evidenz für die Behandlung von Jugendlichen aus Ergebnissen der Studien bei Erwachsenen auf das Jugendalter extrapoliert und aus klinischen Erfahrungen abgeleitet werden. Auch im Erwachsenenalter gibt es keine für die Behandlung von Persönlichkeitsstörungen zugelassenen Substanzen, sodass eine Pharmakotherapie bei diesem Störungsbild immer eine Off-Label-Verschreibung darstellt. Zur Behandlung der Kernsymptome sind spezifische Psychotherapieverfahren das Mittel der Wahl. Zur Behandlung von einzelnen Symptomen oder Komorbiditäten können Neuro-/Psychopharmaka sinnvoll als Komplementärtherapie eingesetzt werden. Die größte empirische Evidenz (bezogen auf das Erwachsenenalter) findet sich für Antipsychotika der zweiten und dritten Generation sowie für selektive Serotonin-Wiederaufnahmehemmer und Stimmungsstabilisatoren. Interessante Behandlungsansätze könnten sich zukünftig mit Omega-3-Fettsäuren oder Oxytocin ergeben. Es ist dringend erforderlich, dass in Zukunft auch im Jugendalter systematische Studien zur Wirksamkeit und zu den unerwünschten Arzneimittelwirkungen von psychotropen Substanzen durchgeführt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Amminger GP, Chanen AM, Ohmann S et al (2013) Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can J Psychiatry 58:402–408

    PubMed  Google Scholar 

  • Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2011) AWMF S2-Leitlinie Psychiatrie: Persönlichkeitsstörungen. AWMF-Leitlinien-Register Nr. 038/015. http://www.awmf.org/uploads/tx_szleitlinien/038-015m_01.pdf. Zugegriffen: 6. Juni 2013

    Google Scholar 

  • Bateman AW, Fonagy P (2000) Effectiveness of psychotherapeutic treatment of personality disorder. Brit J Psychiatry 177:138–143

    Article  CAS  Google Scholar 

  • Becker DF, Grilo CM, Morey LC, Walker ML, Edell WS, McGlashan TH (1999) Applicability of personality disorder criteria to hospitalized adolescents: evaluation of internal consistency and criterion overlap. J Am Acad Child Adol Psychiatry 38:200–205

    Article  CAS  Google Scholar 

  • Bellino S, Paradiso E, Bogetto F (2005) Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 66:1111–1115

    Article  CAS  PubMed  Google Scholar 

  • Bellino S, Rinaldi C, Bozzatello P, Bogetto F (2011) Pharmacotherapy of borderline personality disorder: A systematic review for publication purpose. Curr Med Chem 18:3322–3329

    Article  CAS  PubMed  Google Scholar 

  • Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E (1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 59:103–107

    Article  CAS  PubMed  Google Scholar 

  • Bertsch K, Gamer M, Schmidt B et al (2013) Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. Am J Psychiatry 170:1169–1177

    Article  PubMed  Google Scholar 

  • Birmaher B, Axelson DA, Monk K et al (2003) Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:415–423

    Article  PubMed  Google Scholar 

  • Bogenschutz MP, Nurnberg GH (2004) Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 65:104–109

    Article  CAS  PubMed  Google Scholar 

  • Chanen AM, Jackson HJ, McCutcheon L et al (2008) Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: a randomised controlled trial. Br J Psychiatry 193:477–484

    Article  PubMed  Google Scholar 

  • Coccaro EF (1993) Psychopharmacologic studies in patient with personality disorders: review and perspective. J Personal Disord 154(Suppl 2):181–192

    Google Scholar 

  • Coccaro EF, Kavoussi RJ (1997) Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 54:1081–1088

    Article  CAS  PubMed  Google Scholar 

  • Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotics during first-time use in children and adolescents. JAMA 302:1765–1773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cowdry R, Gardner DL (1988) Pharmacotherapy in borderline personality disorder. Arch Gen Psychiatry 45:111–119

    Article  CAS  PubMed  Google Scholar 

  • de la Fuente JM, Lotstra F (1994) A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 4:479–486

    Article  PubMed  Google Scholar 

  • Dilling H, Mombour W, Schmidt MH (Hrsg) (2013) Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien, 9. Aufl. Huber, Bern

    Google Scholar 

  • Ekselius L, von Knorring L (1998) Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. Int Clin Psychopharmacol 13:205–211

    Article  CAS  PubMed  Google Scholar 

  • Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U (1995) Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand 92:351–358

    Article  CAS  PubMed  Google Scholar 

  • Falkai P, Wittchen H-U (Hrsg) (2015) American Psychiatric Association. Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5®. Hogrefe, Göttingen

    Google Scholar 

  • Fleischhaker C (Hrsg) (2011) DBT-A-Manual: Dialektisch-behaviorale Therapie für Jugendliche. Springer, Heidelberg

    Google Scholar 

  • Foelsch P, Schlüter-Müller S, Odom A, Arena H, Borzutzky A, Schmeck K (Hrsg) (2013) Behandlung von Jugendlichen mit Identitätsstörungen (AIT) – Ein integratives Therapiekonzept für Persönlichkeitsstörungen. Springer, Heidelberg

    Google Scholar 

  • Gerlach M, Warnke A (2010) Therapy with mood stabilizers in child and adolescent psychiatry. Psychopharmakotherapie 17:183–187

    Google Scholar 

  • Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO (1986) Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 43:680–686

    Article  CAS  PubMed  Google Scholar 

  • Hallahan B, Hibbeln JR, Davis JM, Garland MR (2007) Omega-3 fatty acid supplementation in patients with recurrent self-harm: Single-centre double-blind randomised controlled trial. Brit J Psychiat 190:118–122

    Article  PubMed  Google Scholar 

  • Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller HJ, WFSBP Task Force on Personality Disorders (2007) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of personality disorders. World J Biol Psychiatry 8:212–244

    Article  PubMed  Google Scholar 

  • Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB (2005) Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 162:621–624

    Article  PubMed  Google Scholar 

  • Hopwood CJ, Newman DA, Donnellan MB et al (2009) The stability of personality traits in individuals with borderline personality disorder. J Abnorm Psychol 118:806–815

    Article  PubMed  PubMed Central  Google Scholar 

  • Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H (2010) Effectiveness of pharmacotherapy for severe personality disorders: Meta-analyses of randomized controlled trials. J Clin Psychiat 71:14–25

    Article  CAS  Google Scholar 

  • Kapfhammer HP (2003) Pharmakotherapie bei Persönlichkeitsstörungen. In: Herpertz S, Saß H (Hrsg) Persönlichkeitsstörungen. Thieme, Stuttgart, S 152–164

    Google Scholar 

  • Kavoussi RJ, Coccaro EF (1998) Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 59:676–680

    Article  CAS  PubMed  Google Scholar 

  • Kavoussi RJ, Liu J, Coccaro EF (1994) An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 55:137–141

    CAS  PubMed  Google Scholar 

  • Keshavan M, Shad M, Soloff P, Schooler N (2004) Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 71:97–101

    Article  PubMed  Google Scholar 

  • Kirrane RM, Siever LJ (2000) New perspectives on schizotypical personality disorder. Curr Psychiatry Rep 48:1–5

    Google Scholar 

  • Knappich M, Hörz-Sagstetter S, Schwerthöffer D, Leucht S, Rentrop M (2014) Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices. Int Clin Psychopharmacol 29:224–228

    Article  PubMed  PubMed Central  Google Scholar 

  • Koenigsberg HW, Reynolds D, Goodman M et al (2003) Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 64:628–634

    Article  CAS  PubMed  Google Scholar 

  • Leiberich P, Nickel MK, Tritt K, Pedrosa GF (2008) Lamotrigine treatment of aggression in female borderline patients. Part II: an 18-month follow-up. J Psychopharmacol 22:805–808

    Article  CAS  PubMed  Google Scholar 

  • Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM (2010) Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Brit J Psychiat 196:4–12

    Article  PubMed  Google Scholar 

  • Lieb K, Stoffers J, Dulz B (2014) Pharmakologische Behandlung von Borderline-Persönlichkeitsstörungen. Empfehlung der Gesellschaft zur Erforschung und Therapie von Persönlichkeitsstörungen e.V. Nervenheilkunde 33:720–722

    Google Scholar 

  • Links PS, Steiner M, Boiago I (1990) Lithium therapy for borderline patients: preliminary findings. J Pers Dis 4:173–181

    Article  Google Scholar 

  • Loew TH, Nickel MK (2008) Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up. J Clin Psychopharmacol 28:355–357

    Article  PubMed  Google Scholar 

  • Loose C (2015) Die Schematherapie bei adoleszenten Patienten mit Borderline-Störung. Persönlichkeitsstörungen: Theorie Therapie 19:44–54

    Google Scholar 

  • Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M (2000) A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorders. Arch Gen Psychiatry 57:649–654

    Article  CAS  PubMed  Google Scholar 

  • March JS, reatment for Adolescents With Depression Study (TADS) Team (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807–820

    Article  CAS  PubMed  Google Scholar 

  • Markovitz PJ, Wagner SC (1995) Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 31:773–777

    CAS  PubMed  Google Scholar 

  • National Collaborating Centre for Mental Health (2005) Depression in children and young people. Identification and management in primary, community and secondary care in National Clinical Practice Guideline Number 28. The British Psychological Society & The Royal College of Psychiatrists, London, S 233

    Google Scholar 

  • National Health and Medical Research Council (2012) Clinical practice guideline for the management of borderline personality disorder. National Health and Medical Research Council, Melbourne

    Google Scholar 

  • National Health and Medical Research Council (2013) Caring for people with borderline personality disorder: A reference guide for health professionals. National Health and Medical Research Council, Melbourne

    Google Scholar 

  • NICE (National Institute for Health and Clinical Excellence) (2009) Borderline personality disorder – Treatment and management. NICE clinical guideline 78. http://www.guidance.nice.org.uk/cg78. Zugegriffen: 13. Nov. 2015

    Google Scholar 

  • Nickel MK, Nickel C, Kaplan P et al (2005) Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 57:495–499

    Article  CAS  PubMed  Google Scholar 

  • Nickel MK, Muehlbacher M, Nickel C et al (2006) Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind placebo-controlled study. Am J Psychiatry 163:833–838

    Article  PubMed  Google Scholar 

  • Nickel MK, Loew TH, Pedrosa GF (2007) Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology 191:1023–1026

    Article  CAS  PubMed  Google Scholar 

  • Nosé M, Cpriani A, Biancosino B, Grassi L, Barbui C (2006) Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 21:345–353

    Article  PubMed  Google Scholar 

  • Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS (2006) Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Cdn Acad Child Adolesc Psychiatry 15:27–39

    Google Scholar 

  • Paris J (2002) Chronic suicidality among patients with borderline personality disorder. Psychiatr Serv 53:738–742

    Article  PubMed  Google Scholar 

  • Paris J (2011) Pharmacological treatments for personality disorders. Int Rev Psychiatr 23:303–309

    Article  Google Scholar 

  • Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, Pérez V (2008) Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 69:603–608

    Article  CAS  PubMed  Google Scholar 

  • Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR (2015) (2015) The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry 76:e512

    Article  PubMed  Google Scholar 

  • Quante A, Röpke S, Merkl A, Anghelescu I, Lammers CH (2008) Pharmakologische Behandlung von und bei Persönlichkeitsstörungen. Fortschr Neurol Psychiat 76:139–148

    Article  CAS  PubMed  Google Scholar 

  • Ripoll LH, Triebwasser J, Siever LJ (2011) Evidence-based pharmacotherapy for personality disorders. Int Clin Neuropsychoph 14:1257–1288

    Article  Google Scholar 

  • Rocca P, Marchiaro L, Cocuzza E, Bogetto F (2002) Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 63:241–244

    Article  CAS  PubMed  Google Scholar 

  • Rossouw TI, Fonagy P (2012) Mentalization-based treatment for self-harm in adolescents: A randomized controlled trial. J Am Acad Child Adolesc Psychiatry 51:1304–1313

    Article  PubMed  Google Scholar 

  • Salzman C, Wolfson AN, Schatzberg A et al (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15:23–29

    Article  CAS  PubMed  Google Scholar 

  • Schmahl C, Kleindienst N, Limberger M et al (2012) Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol 27:61–68

    Article  PubMed  Google Scholar 

  • Schmeck K, Schlüter-Müller S (Hrsg) (2009) Persönlichkeitsstörungen im Jugendalter. Springer, Berlin

    Google Scholar 

  • Schmeck K, Schlüter-Müller S (2012) Verlauf und Prognose der schweren Persönlichkeitsstörungen. Swiss Arch Neurol Psychiatry 163:166–170

    Google Scholar 

  • Schmeck K, Schlüter-Müller S, Resch F (2011) Persönlichkeitsstörungen. In: Fegert JM, Eggers C, Resch F (Hrsg) Lehrbuch der Kinder- und Jugendpsychiatrie, 2. Aufl. Springer, Heidelberg, S 635–652

    Google Scholar 

  • Schultz SC, Camlin KL, Berry SA, Jesberger JA (1999) Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 46:1429–1435

    Article  Google Scholar 

  • Schuppert HM, Timmerman ME, Bloo J et al (2012) Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. J Am Acad Child Adol Psych 51:1314–1321

    Article  Google Scholar 

  • Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, Pearlstein T (2004) Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 65:379–385

    Article  CAS  PubMed  Google Scholar 

  • Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, Pérez V (2005) Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 162:1221–1224

    Article  PubMed  Google Scholar 

  • Soloff PH, Nathan RS, George APM, Cornelius JR, Perel JM, Ulrich RF (1986) Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 50:377–385

    Article  Google Scholar 

  • Soloff PH, Nathan RS, George A, Schultz PM, Cornelius JR, Perel JM, Ulrich RF (1993) Progress in pharmacotherapy of borderline disorders: a double blind study of amitriptyline, haloperidol and placebo. Arch Gen Psychiatry 43:691–697

    Article  Google Scholar 

  • Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K (2012) Psychological therapies for people with borderline personality disorder. Cochrane Db Syst Rev 8:CD005652

    Google Scholar 

  • Triebwasser J, Siever LJ (2007) Pharmacotherapy of personality disorders. J Ment Health 16:5–50

    Article  Google Scholar 

  • Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, Nickel MK (2005) Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 19:287–291

    Article  CAS  PubMed  Google Scholar 

  • Tyrer P, Reed GM, Crawford MJ (2015) Classification, assessment, prevalence, and effect of personality disorder. Lancet 385:717–726

    Article  PubMed  Google Scholar 

  • Verkes RJ, Van der Mast RC, Hengeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM (1998) Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 155:543–547

    Article  CAS  PubMed  Google Scholar 

  • Villeneuve E, Lemelin S (2005) Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 66:1298–1303

    Article  CAS  PubMed  Google Scholar 

  • Wewetzer C, Herpertz S, Herpertz-Dahlmann B, Oehler K-U (2007) Persönlichkeitsstörungen (F60, F61. In: Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie, Bundesarbeitsgemeinschaft Leitender Klinikärzte für Kinder- und Jugendpsychiatrie und Psychotherapie, Bundesverband der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie (Hrsg) Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter, 3. Aufl. Deutscher Ärzte-Verlag, Köln, S 141–152

    Google Scholar 

  • Zanarini MC, Frankenburg FR (2001) Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 62:849–854

    Article  CAS  PubMed  Google Scholar 

  • Zanarini MC, Frankenburg FR (2003) Omega-3 Fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. Am J Psychiat 160:167–169

    Article  PubMed  Google Scholar 

  • Zanarini MC, Frankenburg FR, Parachini EA (2004) A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 7:903–907

    Article  Google Scholar 

  • Zanarini MC, Schulz SC, Detke HC et al (2011) A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12 week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 72:1353–1362

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kinder und jugendpsychiatrische Klinik, Universitäre Psychiatrische Kliniken Basel, Schanzenstr. 13, 4056, Basel, Schweiz

    Prof. Dr. med. Klaus Schmeck

  2. Klinik und Poliklinik für Kinder- u. Jugendpsychiatrie, Psychosomatik u. Psychotherapie, Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Füchsleinstraße 15, 97080, Würzburg, Deutschland

    Prof. Dr. med. Marcel Romanos

Authors
  1. Prof. Dr. med. Klaus Schmeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Marcel Romanos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Schmeck .

Editor information

Editors and Affiliations

  1. Zentrum für Seelische Gesundheit, Universitätsklinikum Würzburg, Würzburg, Germany

    Manfred Gerlach

  2. Privatklinik für Seelische Gesundheit, J, HEMERA Klinik, Bad Kissingen, Germany

    Claudia Mehler-Wex

  3. Zentrum für Kinder- und Jugendpsychiatri, Universität Zürich, Zürich, Zürich, Switzerland

    Susanne Walitza

  4. Zentrum für Seelische Gesundheit, Universitätsklinikum Würzburg, Würzburg, Bayern, Germany

    Andreas Warnke

  5. Abteilung Kinder Jugendpsychiatrie, Kliniken der Stadt Köln gGmbH, Köln, Germany

    Christoph Wewetzer

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schmeck, K., Romanos, M. (2016). Persönlichkeitsstörungen. In: Gerlach, M., Mehler-Wex, C., Walitza, S., Warnke, A., Wewetzer, C. (eds) Neuro-/Psychopharmaka im Kindes- und Jugendalter. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48624-5_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48624-5_21

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48623-8

  • Online ISBN: 978-3-662-48624-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation